VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Organogenesis Holdings Executive Compensation (FY25)

ORGO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Gary Gillheeney
Latest say-on-pay support
=
June 15, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Organogenesis Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 16, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Organogenesis Holdings brief$500Get the executive brief
Velarion Intel, one year, every company
298 figures on this page: 293 cited to the filing that reported them, 5 calculated from figures it prints. See the citations

More on Organogenesis Holdings

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Gary Gillheeney: $6,993,679 → $6,811,754 (2.6% lower)
Say-on-pay support: 91.4% → 85.1% (6.3 points lower)
CEO pay ratio: 31:1 → 17:1 (45.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Organogenesis Holdings' chief executive and what were they paid?
Gary Gillheeney was paid $6,811,754 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $6,993,679 reported for fiscal 2024, Gillheeney's total was 2.6% lower.
What was Organogenesis Holdings' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 85.1% of votes cast for or against in favor at the meeting held June 15, 2026.
Which companies are in Organogenesis Holdings' peer group?
Companies named in the disclosed peer group include Alphatec Holdings, Inc., AngioDynamics, Inc., Anika Therapeutics, Inc., Artivion, Inc and AtriCure, Inc., among others.
What is Organogenesis Holdings' chief executive pay ratio?
The company reported a chief executive pay ratio of 17:1 for fiscal 2025, against median employee compensation of $411,028.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Gillheeney
President and Chief Executive Officer Principal Executive Officer
◇◇◇◇——◇◇
Patrick Bilbo
Chief Operating Officer
◇◇◇◇——◇◇
Brian Grow
Chief Commercial Officer
◇◇◇◇——◇◇
Lori Freedman
Chief Administrative and Legal Officer
◇◇◇◇——◇◇
David Francisco
Chief Financial Officer Principal Financial Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Gillheeney
President and Chief Executive Officer
◇◇◇◇——◇◇
Patrick Bilbo
Chief Operating Officer
◇◇◇◇——◇◇
Lori Freedman
Chief Administrative and Legal Officer
◇◇◇◇——◇◇
Brian Grow
Chief Commercial Officer
◇◇◇◇——◇◇
David Francisco
Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Gillheeney
President and Chief Executive Officer
◇—◇◇◇—◇◇
Patrick Bilbo
Chief Operating Officer
◇—◇◇◇—◇◇
Brian Grow
Chief Commercial Officer
◇—◇◇◇—◇◇
David Francisco
Chief Financial Officer
◇◇◇◇◇—◇◇
Lori Freedman
Chief Administrative and Legal Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Gillheeney
President and Chief Executive Officer
◇—◇◇◇—◇◇
Brian Grow
Chief Commercial Officer
◇—◇◇◇—◇◇
Patrick Bilbo
Chief Operating Officer
◇—◇◇◇—◇◇
Lori Freedman
Chief Administrative and Legal Officer
◇—◇◇◇—◇◇
David Francisco
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian GrowPSU◇◇◇—◇—◇
Brian GrowRSU◇——◇——◇
Brian GrowOPTION◇——◇—◇◇
David FranciscoPSU◇◇◇—◇—◇
David FranciscoRSU◇——◇——◇
David FranciscoOPTION◇——◇—◇◇
Gary S. Gillheeney Sr.RSU◇——◇——◇
Gary S. Gillheeney Sr.PSU◇◇◇—◇—◇
Gary S. Gillheeney Sr.OPTION◇——◇—◇◇
Lori FreedmanPSU◇◇◇—◇—◇
Lori FreedmanRSU◇——◇——◇
Lori FreedmanOPTION◇——◇—◇◇
Patrick BilboRSU◇——◇——◇
Patrick BilboPSU◇◇◇—◇—◇
Patrick BilboOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Gary GillheeneyRSU◇◇——
Option◇—◇2/21/2034
Option◇—◇2/22/2033
Option◇—◇2/19/2035
PSU◇◇——
Option◇—◇2/15/2032
Patrick BilboRSU◇◇——
Option◇—◇2/21/2034
Option◇—◇2/22/2033
Option◇—◇2/19/2035
PSU◇◇——
Option◇—◇2/15/2032
Brian GrowRSU◇◇——
Option◇—◇2/21/2034
Option◇—◇2/19/2035
Option◇—◇2/22/2033
PSU◇◇——
Option◇—◇2/15/2032
Lori FreedmanRSU◇◇——
Option◇—◇2/21/2034
Option◇—◇2/19/2035
Option◇—◇2/22/2033
PSU◇◇——
Option◇—◇2/15/2032
David FranciscoRSU◇◇——
Option◇—◇2/21/2034
Option◇—◇2/19/2035
Option◇—◇2/22/2033
PSU◇◇——
Option◇—◇2/15/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Gary Gillheeney
President and Chief Executive Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur S. Leibowitz
◇◇————◇
Jon Giacomin
◇◇————◇
Garrett Lustig
◇◇————◇
Michele Korfin
◇◇————◇
Prathyusha Duraibabu
◇◇————◇
Gilberto Quintero
◇◇————◇
Michael J. Driscoll
◇◇————◇
Gary S. Gillheeney Sr, Alan A. Ades, Glenn H. Nussdorf, David Erani and Robert Ades served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alphatec Holdings, Inc. ATEC
  • AngioDynamics, Inc. ANGO
  • Anika Therapeutics, Inc. ANIK
  • Artivion, Inc AORT
  • AtriCure, Inc. ATRC
  • Avanos Medical, Inc. AVNS
  • AxoGen, Inc. AXGN
  • Bioventus Inc. BVS
  • CONMED Corporation CNMD
  • Embecta Corp. EMBC
  • Integra LifeSciences Holdings Corporation IART
  • MiMedx Group, Inc. MDXG
  • Nevro Corp. NVRO
  • OraSure Technologies, Inc. OSUR
  • Orthofix Medical Inc. OFIX
  • Pacira BioSciences, Inc. PCRX
  • Paragon 28, Inc. FNA
  • Tactile Systems Technology, Inc. TCMD
  • Vanda Pharmaceuticals Inc. VNDA
  • ZimVie Inc. ZIMV

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 15, 2026=◇◇◇
2024June 23, 2025=◇◇◇
2023June 20, 2024=◇◇◇
2022June 13, 2023=◇◇◇
2021June 23, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Gary Gillheeney (President and Chief Executive Officer), FY2025 total compensation $6,811,754 (base salary $979,105) [exec_comp, SEC accession 0001193125-26-197357, filed 2026-04-30]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Organogenesis Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Organogenesis Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Organogenesis Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Organogenesis Holdings' disclosed peer group is defensible, who names Organogenesis Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
298 figures on this page: 293 cited to the filing that reported them, 5 calculated from figures it prints.
293 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-26-272710
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001193125-26-197357
    2025 Grants of Plan-Based Awards · CEO Pay Ratio · Director Compensation · Outstanding Equity Awards at Fiscal 2025 Year End · and 2 more sections
  3. 0001193125-25-145767
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001193125-24-165670
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  5. 0001193125-23-168964
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  6. 0001193125-23-130412
    Summary Compensation Table for Fiscal Year 2022
  7. 0001193125-22-182860
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Organogenesis Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ORGO (accessed 2026).
Short form: data: Velarion

The paid brief for Organogenesis Holdings

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Organogenesis Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Organogenesis Holdings discloses

The companies named in ORGO's own disclosed peer group.

Alphatec Holdings, Inc.AngioDynamics, Inc.Anika Therapeutics, Inc.Artivion, IncAtriCure, Inc.Avanos Medical, Inc.AxoGen, Inc.Bioventus Inc.CONMED CorporationEmbecta Corp.Integra LifeSciences Holdings CorporationMiMedx Group, Inc.Nevro Corp.OraSure Technologies, Inc.Orthofix Medical Inc.Pacira BioSciences, Inc.Paragon 28, Inc.Tactile Systems Technology, Inc.Vanda Pharmaceuticals Inc.ZimVie Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy